Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study

Coronary Artery Disease Clinical Trial

Official title:

A Randomized Controlled Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART-II

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03284255
• Other study ID #: BXA2017001
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 11, 2017
• Est. completion date: August 30, 2024

Study information

• Verified date: November 2019
• Source: Shanghai Bio-heart Biological Technology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Bioheart Randomized Controlled Trial is a prospective multicentred paralleled study, which will enroll 430 patients and randomized 1:1 to study group and control group. Aim to assess the efficacy and safety of Rapamycin Drug-Eluting Bioresorbable Coronary Stent System compare with XIENCE stent in the treatment of patients with up to two coronary lesions.

Description:

This study is a prospective, multicentred randomized controlled trial, planning to enroll 430 subjects and randomize 1:1 to study group and control group.

All subjects will accept clinical evaluation at 1 month, 6 month, 9 month and 1, 2, 3, 4, 5 year post procedure.

All subjects will accept angiographic evaluation at 1 year post procedure, and simutaneously 80 subjects (40 in study group and 40 in control group) will accepted OCT evaluation.

To assess the efficacy and safety, the primary endpoint will be in segment late luminal loss at 1 year post procedure, the secondary endpoint is neointima coverage percentage of stent strut (%) at 1 year post procedure.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 431
• Est. completion date: August 30, 2024
• Est. primary completion date: August 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

subjects that participate in this study must fulfill all the following criteria:

general inclusion criteria:

1. Age from 18 to 75 years old, man or non-pregnant woman;

2. Subjects with asymptomatic ischemic evidence, stable or unstable angina, or old myocardial infarction, suitable for selective PCI;

3. Subjects without contraindications of coronary artery bypass grafting (CABG);

4. Subjects are able to understand the purpose of this study, volunteer to participate and sign informed consent, willing to accept invasive imaging follow-up.

Angiographic inclusion criteria:

1. One or two de novo target lesions

1. If subject has only one target lesion, the second non-target lesion can be treated but this non-target lesion must locate in a different epicardial vessel, and must be treated first and be treated successfully prior to the subjects' randomization.

2. If there are two target lesions, they must locate in different epicardial vessels and both satisfy the angiographic eligibility criteria.

3. The definition of epicardial vessels means the left anterior descending artery (LAD), the left circumflex artery (LCX), and the right coronary artery (RCA) and their branches. Thus, for example, the subject must not have lesions requiring treatment in both the LAD and a diagonal branch

2. Target lesion diameter stenosis = 70% (or = 50% simultaneously shall have clinical evidence of myocardial ischemia), and TIMI flow grade =1; Target lesion length =24mm (visually); target lesion diameter between = 2.5 mm to = 4.00 mm.

3. Each target lesion can be fully covered by one stent.

Exclusion Criteria:

If subjects fulfill any of below criterias, this subject shall be exclude from this study.

general exclusion criteria:

1. Any newly onset acute myocardial infarction within 1 week or, myocardial enzymes does not return to normal level after myocardial infarction;

2. Target lesion has any stents implant history within 1 year or subjects planning to receive percutaneous artery intervention within half one year;

3. Subjects with severe heart failure (= grade III NYHA) or left ventricular ejection fraction <35% (accessed by ultrasound or left ventricular angiography)

4. Preprocedure severe kidney functional damaged: serum creatinine> 2.0mg /dl (176.8µmol / L) or subject is receiving hemodialysis;

5. Subjects with bleeding tendency, active gastrointestinal ulcers, history of cerebral hemorrhage or history of subarachnoid hemorrhage, history within six months of ischemic stroke, contraindications of anti-platelet agents and anticoagulants treatment, and subjects cannot receive anti-thrombolytic therapy;

6. Hypersensitive or allergic to aspirin, clopidogrel, heparin, contrast agent, polylactic acid polymer, rapamycin;

7. The subject's life expectancy is less than 24 months;

8. Subjects participated in other drug or medical device clinical trial and have not reach the primary endpoint;

9. Investigators determine the subjects' compliance is poor, cannot complete the study as required;

10. Subjects have accepted substantial organ transplant or ready to undergo organ transplant;

11. Subjects have unstable arrhythmia, such as high-risk ventricular premature beats, and ventricular tachycardia;

12. Subjects need to receive chemotherapy because of tumor;

13. Subjects have received or planning to receive coronary or chest radiotherapy;

14. Subjects with Immunosuppressive, autoimmune diseases, are planned or undergoing immunosuppressive therapy;

15. Subjects are planning to receive or are receiving long-term anticoagulation therapy, such as heparin, warfarin and so on;

16. Subjects are planning to accept selective surgery within 6 months, need to discontinue aspirin or clopidogrel;

17. Blood tests showed that the platelet count is less than 100 × 109 / L, or over than 700 × 109 / L, the white blood cells count is less than 3 × 109 / L;

18. Diagnosed or suspected liver disease (such as hepatic cirrhosis);

19. Subjects with diffuse peripheral vascular disease, cannot use 6F catheter.

angiographic exclusion criteria

these exclusion criteria apply to the target or non-target lesion(s), target or non-target vessel(s)

1. Target or non-target lesion(s) located in left main;

2. Subjects with coronary artery triple vessel lesion in LAD, LCX or RCA, all need to be treated.

these exclusion criteria apply to the target lesion(s) or target vessel(s)

1. Target lesion located in left main;

2. Target lesion located in the aorto-ostial of RCA (within 3 mm of the origin of the RCA);

3. Target lesion located within 3 mm of the origin of the LAD and LCX;

4. Lesion involving a bifurcation with a:

1. Side branch = 2.5 mm in diameter, or

2. Side branch with diameter stenosis = 50%, or

3. Side branch requiring protection guide wire, or

4. Side branch requiring pre-dilatation.

5. Anatomy proximal to or within the lesion that may affect delivery of the Bioheart or XIENCE stent, including:

1. Extreme angulation (= 90°) proximal to or within the target lesion, or

2. Excessive tortuosity (= two 45° angles) proximal to or within the target lesion, or

3. Moderate or heavy calcification proximal to or within the target lesion

6. Target lesion involves a myocardial bridge.

7. Target vessel contains thrombus as indicated in the angiographic images or IVUS.

8. Prior to the index procedure target vessel has been previously treated with a stent at any time such that the Bioheart or XIENCE stent would need to cross the stent to reach the target lesion.

9. Target vessel has been previously treated with a stent and the target lesion is within 5 mm proximal to a previously treated lesion.

10. Target lesion cannot reach the following outcomes, after the complete balloon pre-dilatation:

1. Residual (DS %) is < 40% (per visual estimation), = 20% is strongly recommended;

2. TIMI Grade-3 flow (per visual estimation);

3. No angiographic complications (e.g., no-reflow, distal embolization, side branch closure)

4. No dissections NHLBI grade D-F;

5. No chest pain lasting > 5 minutes, and;

6. No ST depression or elevation lasting > 5 minutes.

Related Conditions & MeSH terms

• Antineoplastic Agents
• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• study group
study group in which patient will accept the treatment of Bioresorbable Coronary Stent
• control group
control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®

Locations

Country	Name	City	State
China	Beijing Anzhen Hospital Capital Medical University	Beijing	Beijing
China	BeijingChao-YangHospital	Beijing	Beijing
China	Fuwai Hospital Chinese Academy of Medical Sciences	Beijing	Beijing
China	Cangzhou Central Hospital	Cangzhou	Hebei
China	The Second Hospital of Jilin University	Changchun	Jilin
China	Xiangya Hospital Central South University	Changsha	Hunan
China	The First Affiliated Hospital of Dalian Medical University	Dalian	Liaoning
China	Fujian Provincial Hospital	Fuzhou	Fujian
China	Nanfang Hospital	Guangzhou	Guangdong
China	The Frist Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong
China	Zhujiang Hospital of Southern Medical University	Guangzhou	Guangdong
China	Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine	Hangzhou	Zhejiang
China	Inner Mongolia Autonomous Region People's Hospital	Hohhot	The Inner Mongolia Autonomous Region
China	Qilu Hospital of Shandong University	Jinan	Shandong
China	Liaocheng People's Hospital	Liaocheng	Shandong
China	The People's Hospital of Guangxi Zhuang Autonomous Region	Nanning	Guangxi
China	Shanghai Dongfang Hospital	Shanghai	Shanghai
China	Shanghai Sixth People's Hospital	Shanghai	Shanghai
China	Tangshan Gongren Hospital	Tangshan	Hebei
China	Taida International Cardioascular Hospital	Tianjin	Tianjin
China	The First Affiliated Hospital of Wenzhou Medical University	Wenzhou	Zhejiang
China	Tangdu Hospital-Fourth Military Medical University	Xi'an	Shanxi
China	The Affiliated Hospital of Xuzhou Medical University	Xuzhou	Jiangsu
China	The First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan
China	Zhongshan People's Hospital	Zhongshan	Gunagdong

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai Bio-heart Biological Technology Co., Ltd.	CCRF Inc., Beijing, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	angiographic endpoints-acute stent recoil	assess in milimeter	immediately post procedure
Other	angiographic endpoints-late lumen loss (LLL)	include in stent, 5mm proximal and distal to the stent;	immediately and 1 year post procedure
Other	angiographic endpoints-minimal lumen diameter (MLD)	include in stent, 5mm proximal and distal to the stent and in segment;	immediately and 1 year post procedure
Other	angiographic endpoints-diameter stenosis (DS),	assess in percentage, include in stent, 5mm proximal and distal to the stent and in segment;	immediately and 1 year post procedure
Other	angiographic endpoints-angiographic binary restenosis (ABR),	assess in percentage, include in stent, 5mm proximal and distal to the stent and in segment.	1 year post procedure
Other	OCT imaging endpoints-Neointimal tissue thickness	assess in millimeter	1 year post procedure
Other	OCT imaging endpoints-late acquired stent malapposition	assess in millimeter	1 year post procedure
Other	OCT imaging endpoints-Volume obstruction percentage	assess in percentage	1 year post procedure
Other	OCT imaging endpoints-Late stent recoil	assess both in percentage and square millimeter	1 year post procedure
Other	OCT imaging endpoints-Neointimal Healing Score	will be calculated by OCT imaging software	1 year post procedure
Primary	in segment late luminal loss	In-segment late loss is defined as the change in minimal lumen diameter (MLD) from post-procedure to 1 year by angiography,in segment is defined within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent.	1 year post procedure
Primary	neointima coverage percentage of stent strut (%)	only in OCT subgroup	1 year post procedure
Secondary	device success	defined as attainment of residual stenosis less than 30% by visual estimation and TIMI flow grade 3 post stent implantation	immediately post procedure
Secondary	lesion success	defined as attainment of diameter residual stenosis less than 30% by visual estimation and TIMI flow grade 3, after the target lesion treated by any PCI methods	immediately post procedure
Secondary	clinical success	defined as attainment of lesion success and without any major adverse cardiac events during hospitalization (up to 7 days after proceduce)	at 1 month post procedure
Secondary	Device oriented composite endpoint (DoCE)/target lesion failure (TLF)	defined as Cardiac Death, target vessel - myocardial infarction (TV-MI), and ischemic driven - target lesion revascularization (ID-TLR)	at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
Secondary	Patient oriented composite endpoint (PoCE)	defined as all caused death, any myocardial infarction, and any revascularization.	at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
Secondary	death	cardiac death, vascular death, non-cardiovascular death	at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
Secondary	myocardial infarction (MI)	target vessel MI, non-target vessel MI	at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
Secondary	target lesion revascularization	ischemic driven, non-ischemic driven	at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
Secondary	target vessel revascularization	ischemic driven, non-ischemic driven	at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
Secondary	any coronary revascularization		at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
Secondary	ARC--defined stent thrombosis	timing (acute, subacute, late and very late stent thrombosis); relationship (definite, probable and possible stent thrombosis)	at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure